The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Open accessAbstract
BACKGROUND: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. METHODS: A total of 1156 patients not previously treated with lamivudine or protease inhibitors were stratified according to CD4 cell count (50 or fewer vs. 51 to 200 cells per cubic millimeter) and randomly assigned to one of two daily regimens: 600 mg of zidovudine (or stavudine) and 300 mg of lamivudine, or that regimen with 2400 mg of indinavir. The primary end point was the time to the development of the acquired immunodeficiency syndrome (AIDS) or death. RESULTS: The proportion of patients whose disease progressed to AIDS or death was lower with indinavir, zidovudine, and lamivudine (6 percent) than with zidovudine and lamivudine alone (11 percent; estimated hazard ratio, 0.50; 95 percent confidence interval, 0.33 to 0.76; P=0.001). Mortality in the two groups was 1.4 percent and 3.1 percent, respectively (estimated hazard ratio, 0.43; 95 percent confidence interval, 0.19 to 0.99; P=0.04). The effects of treatment were similar in both CD4 cell strata. The responses of CD4 cells and plasma HIV-1 RNA paralleled the clinical results. CONCLUSIONS: Treatment with indinavir, zidovudine, and lamivudine as compared with zidovudine and lamivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidovudine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
Viral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
Mellors, J. W., Rinaldo, C. R., Gupta, P., White, R. M., Todd, J. A., & Kingsley, L. A. (1996) · Science · doi:10.1126/science.272.5265.1167 · Cited by 2,660
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection
Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-12-199706150-00003 · Cited by 2,067
Self-citationGulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,885
Self-citationActive human immunodeficiency virus protease is required for viral infectivity
Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A., Scolnick, E. M., & Sigal, I. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4686 · Cited by 1,307
Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351501 · Cited by 1,091
Self-citationQuantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion
Mellors, J. W., Kingsley, L. A., Rinaldo, C. R., Todd, J. A., Hoo, B. S., Kokka, R. P., & Gupta, P. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00003 · Cited by 917
Host factors and the pathogenesis of HIV-induced disease
Fauci, A. S. (1996) · Nature · doi:10.1038/384529a0 · Cited by 829
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Larder, B. A., Kemp, S. D., & Harrigan, P. R. (1995) · Science · doi:10.1126/science.7542804 · Cited by 623
Quantitative Image Analysis of HIV-1 Infection in Lymphoid Tissue
Haase, A. T., Henry, K., Zupancic, M., Sedgewick, G., Faust, R. A., Melroe, H., Cavert, W., Gebhard, K., Staskus, K., Zhang, Z.-Q., et al. (1996) · Science · doi:10.1126/science.274.5289.985 · Cited by 599
Self-citationDanner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332303 · Cited by 567
Mulder, J., McKinney, N., Christopherson, C., Sninsky, J., Greenfield, L., & Kwok, S. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.2.292-300.1994 · Cited by 558
Eron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332502 · Cited by 531
Self-citationDarbyshire, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05387-1 · Cited by 509
A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., Marca, A. L., Leonard, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332204 · Cited by 493
Katzenstein, D. A., Hammer, S. M., Hughes, M. D., Gundacker, H., Jackson, J. B., Fiscus, S., Rasheed, S., Elbeik, T., Reichman, R., Japour, A., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351502 · Cited by 477
Self-citationPeng, C., Ho, B. K., Chang, T. W., & Chang, N. T. (1989) · Journal of Virology · doi:10.1128/jvi.63.6.2550-2556.1989 · Cited by 371
Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.
Seelmeier, S., Schmidt, H., Turk, V, & von der Helm, K. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.18.6612 · Cited by 328
Hughes, M. D., Johnson, V. A., Hirsch, M. S., Bremer, J. W., Elbeik, T., Erice, A., Kuritzkes, D. R., Scott, W. A., Spector, S. A., Basgoz, N., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-12-199706150-00001 · Cited by 280
Self-citationCarpenter, C. C. J. (1997) · JAMA · doi:10.1001/jama.277.24.1962 · Cited by 268
O'Brien, W. A., Hartigan, P. M., Daar, E. S., Simberkoff, M. S., & Hamilton, J. D. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-12-199706150-00002 · Cited by 259
Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies
Havlir, D. V., & Richman, D. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-11-199606010-00006 · Cited by 204
Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children
Englund, J. A., Baker, C. J., Raskino, C., McKinney, R. E., Petrie, B., Fowler, M. G., Pearson, D. A., Gershon, A. A., McSherry, G., Abrams, E. J., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362403 · Cited by 172
Stopping rules and estimation problems in clinical trials
Hughes, M. D., & Pocock, S. (1988) · Statistics in Medicine · doi:10.1002/sim.4780071204 · Cited by 133
Self-citationStaszewski, S., Loveday, C., Picazo, J. J., Dellarnonica, P., Skinhøj, P., Johnson, M. A., Danner, S. A., Harrigan, P. R., Hill, A. M., Verity, L., et al. (1996) · PubMed · Cited by 113
Bartlett, J. A., Benoit, S. L., Johnson, V. A., Quinn, J. B., Sepulveda, G. E., Ehmann, W. C., Tsoukas, C., Fallon, M. A., Self, P. L., Rubin, M., et al. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-3-199608010-00001 · Cited by 109
Cited by
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003) · Nature Medicine · doi:10.1038/nm880 · Cited by 1,703
Metadata
- Authors
- Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., Chodakewitz, J. A., Fischl, M. A., Phair, J. P., Pedneault, L., Nguyen, B.-Y., & Cook, J. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-09-11
- Volume
- 337
- Issue
- 11
- Pages
- 725-733
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2339219218
- Cited by
- 2,640
- References
- 35
- FWCI
- 207.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.